Kidney care provider Evergreen Nephrology announced that David Young has joined its board of directors. Young has served as chief executive officer (CEO) of GenesisCare, president and CEO of Physicians Endoscopy Inc., and chief operating officer of Privia Health. He has held senior-level positions at Smile Brands Inc., McKesson Specialty Health, and US Oncology Inc. Young will continue to serve on the boards of GenesisCare Cayman Holdings, GenesisCare UK Ltd, and Biocartis Holdings Inc. ...
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
In March, a patient at the Cleveland Clinic became the first in the US to receive a robot-assisted dual kidney transplant.
Are kidneys from donors who had dialysis more likely to result in adverse outcomes for transplant recipients?
A gift from the Schattner Foundation will support the American Kidney Fund's disaster relief program and other programs.
In a phase 2 study, adding tivozanib to nivolumab did not show a benefit for renal cell carcinoma treatment.
The American Heart Association has launched a 4-year plan to improve awareness and treatment of CKM syndrome.
Could a lifestyle intervention intended for overweight or obese diabetes patients improve kidney function?
Researchers examined how cardiovascular health status differs between men and women with kidney failure.
Ardelyx is suing the HHS and CMS over their addition of oral phosphate-lowering drugs to a bundled payment system.
The FDA granted a patent to Unicycive Therapeutics for UNI-494, a drug to treat acute kidney injury (AKI).
The FDA approved Velphoro (sucroferric oxyhydroxide) for hyperphosphatemia in patients with CKD as young as age 9.
Advertisement
Expert Interviews
In Print
NKF Spring Clinical Meetings, ETC payment model, ozone and ESRD risk, IgAN treatments, and more.
Assessing recurrent gout risk, SARS-CoV-2 vaccine response during dialysis, plant-based diets with CKD, and more.
Conferences
ATC provides a forum for exchange of new scientific and clinical information relevant to transplantation.
The annual nephrology meeting organized by the European Renal Association
The National Kidney Foundation's premier educational event designed for the interprofessional kidney health team
The annual scientific, educational, and networking meeting of the International Society of Nephrology
Podcasts
Results of Nefecon (budesonide) for IgA nephropathy set the stage for a glomerulonephritis renaissance.
Vlado Perkovic presented results from the FLOW trial at the 61st ERA Congress, making headlines worldwide.
A blood test may help nephrologists answer the question, “Is this preeclampsia, proteinuric CKD, or a lupus flare?”
Review Dr. Burton Rose's writings on the clinical use of diuretics.
Expert Columns
It is essential for nephrology practices and dialysis centers to have backup methods for processing claims.
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
The choice of a billing solution, often made under the guise of cost savings, requires a thoughtful approach.
Knowledge Hubs
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
